Table 1 Clinical characteristics and anti-diabetes drugs of patients with diabetes receiving COVID-19 vaccines

Age (years)

63.44

(14.52)

65.67

(8.42)

52.62

(11.34)

< 0.001^*

Male gender

89

(56.33%)

132

(57.64%)

46

(68.66%)

0.201

Diabetes duration (years)

9.17

(5.98)

10.57

(6.17)

7.39

(5.5)

< 0.001^*

Type 1 Diabetes

1

(0.63%)

2

(0.87%)

2

(2.99%)

0.269

Alcohol

22

(13.84%)

40

(17.47%)

7

(17.47%)

0.313

Smoker

19

(11.95%)

35

(15.28%)

14

(20.90%)

0.222

Retinopathy

34

(21.38%)

50

(21.83%)

12

(17.91%)

0.782

Proteinuria

56

(35.44%)

87

(37.99%)

23

(34.33%)

0.806

Hypertension

114

(71.70%)

168

(73.36%)

48

(71.64%)

0.922

Coronary heart disease^a

14

(8.81%)

20

(8.73%)

8

(11.94%)

0.709

Cerebrovascular accident^b

14

(8.81%)

14

(6.11%)

3

(4.48%)

0.418

Heart failure

8

(5.03%)

4

(1.75%)

2

(2.99%)

0.183

End-stage renal disease

8

(5.03%)

1

(0.44%)

0

(0.00%)

0.003^*

Anti-Diabetes drugs

 Sulfonylurea

54

(33.96%)

98

(42.79%)

28

(41.79%)

0.119

 Metformin

133

(83.65%)

195

(85.15%)

59

(88.06%)

0.696

 Acarbose

8

(5.03%)

8

(3.49%)

4

(5.97%)

0.609

 Glinide

7

(4.40%)

7

(3.06%)

0

(0.00%)

0.216

 Pioglitazone

5

(3.14%)

6

(2.62%)

1

(1.49%)

0.778

 DPP4i^c

65

(40.88%)

98

(42.79%)

25

(37.31%)

0.718

 SGLT2i^d

28

(17.72%)

34

(14.91%)

21

(31.82%)

0.007^*

 Insulin

30

(18.87%)

56

(24.45%)

15

(22.39%)

0.428

 GLP-1^e analog

6

(3.77%)

11

(4.80%)

3

(4.48%)

0.888

Statins

112

(70.44%)

159

(69.43)

48

(71.64)

0.935